SeaStar Medical Holding Corporation (ICU) 株式分析

企業概要

SeaStar Medical Holding Corporation is a commercial-stage medical device enterprise dedicated to developing a proprietary platform therapy designed to mitigate the adverse consequences of hyperinflammation on vital organs within the United States. The corporation offers the selective cytopheretic device (SCD), which functions as a disease-modifying device intended to alter the clinical course of inflammatory conditions. This entity operates within the Healthcare sector, specifically the Biotechnology industry, positioning it as a specialized player in the development of advanced medical technologies rather than a broad-based pharmaceutical or consumer healthcare provider. The company currently maintains a market capitalization of $16.21M and employs a workforce of 17 individuals, while generating annual revenue of $1.23M based on trailing twelve-month data. These financial metrics indicate that the company operates on a micro-cap scale with limited revenue generation relative to its valuation, suggesting a high-risk profile typical of early-stage biotechnology firms where significant capital is often required to advance product development and secure regulatory approval before achieving substantial commercialization.

財務健全性

The company reported revenue of $1.23M for the trailing twelve months, yet simultaneously recorded a net income of $-12,150,000, revealing a substantial gap that highlights a heavy cost structure driven by research and development expenses or operational inefficiencies common in the biotechnology sector. EBITDA figures are listed as N/A, indicating that the company has not yet reached a stage where earnings before interest, taxes, depreciation, and amortization are a standard metric for assessment. Free cash flow stands at $-9,391,750, which signifies that the company is burning cash to fund its operations and product development, thereby limiting its immediate financial flexibility without access to external capital markets. Gross margin is reported at an impressive 95.7%, suggesting that the core product or service has very low variable costs relative to its selling price, though this does not offset the massive operating losses. In contrast, the operating margin is a negative 718.1% and the profit margin is 0.0%, confirming that operational expenses far exceed gross profits and that the company is not yet profitable. The balance sheet holds $11.98M in cash against $525,000 in debt, resulting in a debt-to-equity ratio of 5.04, which indicates a highly leveraged position relative to equity, although the high cash balance provides a significant cushion against this debt load. The current ratio is 3.63, demonstrating strong short-term liquidity as the company possesses ample current assets to cover its current liabilities. Return on equity is -295.2% and return on assets is -80.9%, metrics that reveal management has yet to generate positive returns on the capital invested in the business, a common characteristic for pre-profitability biotechnology companies.

バリュエーション評価

The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -1.58, implying that expected earnings remain negative in the near future and preventing a traditional valuation based on price-to-earnings multiples. The price-to-book ratio is 1.50, indicating that the market values the company at 1.5 times its book value, which may reflect potential future growth prospects or proprietary technology value despite current losses. The price-to-sales ratio is 13.14, a metric that suggests the market is valuing the company significantly relative to its revenue, a typical valuation multiple for high-growth biotechnology firms where investors pay a premium for future potential rather than current profitability. EV/EBITDA is N/A, reinforcing the inability to value the firm using cash-flow-based multiples given the lack of EBITDA data. The stock's 52-week high is $14.70 and the 52-week low is $2.07, placing the current trading price within a wide volatility range that reflects the speculative nature of the asset. The beta value is -1.19, a negative figure that suggests the stock price moves inversely to the broader market, exhibiting unique volatility characteristics not typically seen in standard equities and adding a layer of complexity to risk assessment.

Growth & Income

Revenue growth year-over-year is reported at 526.9%, indicating a massive expansion in sales activity, while earnings growth is N/A due to the absence of positive net income to compare against. Since earnings are negative, they are not growing faster or slower than revenue in a traditional sense, but rather the company is scaling revenue while still operating at a significant loss, which is a standard phase for commercial-stage medical device companies. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available cash and capital into research, development, and operational expansion rather than distributing income to shareholders. This non-dividend profile aligns with the company's focus on growth and product development rather than income generation, creating a capital-intensive growth strategy typical of the biotechnology industry. The overall growth and income profile is characterized by explosive revenue expansion paired with deep cash burn and no current income distribution, presenting a high-risk, high-potential-reward scenario for investors seeking exposure to early-stage medical innovation.